comparemela.com

Morgan Stanley started coverage on shares of Dyne Therapeutics (NASDAQ:DYN – Get Free Report) in a report released on Tuesday, Briefing.com reports. The firm set an “overweight” rating and a $40.00 price target on the stock. Morgan Stanley’s price target indicates a potential upside of 57.11% from the company’s previous close. A number of other […]

Related Keywords

United States ,Stifel Nicolaus ,Joshuat Brumm ,Raymond James ,Wildon Farwell ,Zurcher Kantonalbank Zurich Cantonalbank ,Raymond James Associates ,York Mellon Corp ,Dyne Therapeutics Inc ,Morgan Stanley ,Securities Exchange Commission ,Allspring Global Investments Holdings ,Td Asset Management Inc ,Dyne Therapeutics ,Get Free Report ,Exchange Commission ,New York Mellon Corp ,Kantonalbank Zurich Cantonalbank ,Management Inc ,Global Investments Holdings ,Dyne Therapeutics Daily ,Nasdaq Dyn ,Ladyn ,Medical ,Initiated Coverage ,

© 2025 Vimarsana

comparemela.com © 2020. All Rights Reserved.